NCT00240435 - 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD | Biotech Hunter

Enrollment

491

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

December 31, 2003

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler

DEVICE

10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler

Trial Locations (25)

Boehringer Ingelheim Investigational Site, Birmingham

Boehringer Ingelheim Investigational Site, Downey

University of California - Los Angeles, Los Angeles

Boehringer Ingelheim Investigational Site, Palo Alto

Rocky Mountain Center for Clinical Research, Wheat Ridge

Boehringer Ingelheim Investigational Site, Bay Pines

Boehringer Ingelheim Investigational Site, Clearwater

Boehringer Ingelheim Investigational Site, Pembroke Pines

Boehringer Ingelheim Investigational Site, Wheaton

Boehringer Ingelheim Investigational Site, St Louis

Boehringer Ingelheim Investigational Site, New Hyde Park

Boehringer Ingelheim Investigational Site, Elizabeth City

Boehringer Ingelheim Investigational Site, Charleston

Boehringer Ingelheim Investigational Site, Dallas

Boehringer Ingelheim Investigational Site, Vancouver

St. Boniface General Hospital, Winnipeg

Boehringer Ingelheim Investigational Site, Courtice

St. Joseph's Hospital Cardiac Research, Hamilton

Boehringer Ingelheim Investigational Site, Toronto

Department of Respiratory Medicine, Toronto

Toronto General Hospital, Toronto

SMBD--Jewish General Hospital, Montreal

Centre de Recherche Clinique -CUSE, Sherbrooke

Hopital Laval, Ste-Foy

c/o Hemodynamics Offices, Saskatoon